Press Releases - NTSAD

Kathleen M Flynn Joins NTSAD as New CEO

sdimond@ntsad.org (Sydnie Dimond) — Wed, 06 Oct 2021 11:30:21 -0400

2020 May 28 NTSAD Hosts Largest and Virtual Family Conference

peg@pegdoyle.com (Peg Doyle) — Thu, 28 May 2020 12:04:45 -0400

Boston, Mass.– National Tay-Sachs & Allied Diseases (NTSAD) kicked off its 42nd Annual Family Conference with a record-breaking turnout of nearly 400 individuals, including individuals and families affected by Tay-Sachs, Canavan, GM1, and Sandhoff, all rare genetic diseases. The four-day event moved from an in-person gathering in Denver, Colorado to a virtual event because of the Covid 19 pandemic.

2018 Dec 13 Press Release Axovant Licenses GM2 and GM1 Gene Therapies

peg@pegdoyle.com (Peg Doyle) — Fri, 14 Dec 2018 08:11:12 -0500

NTSAD Announces Research Initiative Grant Recipients

peg@pegdoyle.com (Peg Doyle) — Mon, 21 Sep 2015 00:54:39 -0400

National Tay-Sachs & Allied Diseases Announces Research Initiative Grant Recipients

Nation’s first patient advocacy organization awards five grants totaling $266,000

September 18, 2015—BOSTON, MA—National Tay-Sachs & Allied Diseases Association (NTSAD), the nation’s first patient advocacy organization, today announced the awardees of its 2015 Innovative Research Grants. Reflecting an ongoing commitment to fund research aligned with its mission to lead the fight to treat and cure Tay-Sachs (TSD), GM-1, Sandhoff, Canavan (CD) and other related genetic diseases, NTSAD has solicited proposals for basic, translational or clinical research projects. This year’s grants include projects related to newborn screening, gene therapy delivery methods, animal models and international patient registries.

NTSAD Corporate Advisory Council Announcement

Diana@ntsad.org (Diana) — Tue, 03 Feb 2015 12:39:36 -0500